Recurrent iritis after implantation of an iris-fixated phakic intraocular lens for the correction of myopia Case report and clinicopathologic correlation.
The iris-claw intraocular lens (IOL) was recently approved by the U.S. Food and Drug Administration for the correction of refractive disorders. Previous reports are not uniform regarding its potential to induce inflammatory reaction. We report the case of a young healthy patient who experienced persistent and intolerable iritis after implantation of an iris-claw IOL. The iritis was resolved only after explantation of the IOL.
Kleinmann
Guy
G
Laboratories for Ophthalmic Devices Research, John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah 84132, USA.
Apple
David J
DJ
Mackool
Richard J
RJ
D020878:Device Removal; D005260:Female; D006801:Humans; D007498:Iris / Q000601:surgery*; D007500:Iritis / Q000209:etiology*; D019654:Lens Implantation, Intraocular / Q000009:adverse effects* / Q000379:methods; D007908:Lens, Crystalline / Q000502:physiology*; D007910:Lenses, Intraocular; D008875:Middle Aged; D009216:Myopia / Q000601:surgery*; D012008:Recurrence; D012086:Reoperation